Gastrointestinal Imaging

Which Imaging Is Best for Staging Primary Liver Cancer in an Adult Patient?

·
Which Imaging Is Best for Staging Primary Liver Cancer in an Adult Patient?

A 67-year-old man with a history of cirrhosis due to nonalcoholic steatohepatitis presents for follow-up after a screening ultrasound revealed a new 3 cm liver lesion. His alpha-fetoprotein (AFP) is elevated. A diagnosis of hepatocellular carcinoma (HCC) is confirmed, and you are now tasked with staging his disease to determine the optimal treatment path—be it surgical resection, liver-directed therapy, or systemic treatment. The critical question is which imaging study will most accurately define the extent of his cancer, assessing for satellite nodules, vascular invasion, and distant spread. This decision directly impacts his prognosis and therapeutic options. According to the American College of Radiology (ACR) Appropriateness Criteria, for this exact scenario, an `MRI abdomen without and with IV contrast` is rated Usually Appropriate.

Who Fits This Clinical Scenario for Primary Liver Cancer Staging?

This guidance applies specifically to adult patients with a newly diagnosed primary liver cancer, most commonly hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma, who require initial staging. The diagnosis may have been established via biopsy or by characteristic imaging features in a high-risk patient (e.g., cirrhosis). The primary clinical goal is to accurately determine the tumor stage, which includes assessing the size and number of intrahepatic tumors, the presence of major vascular invasion, and the extent of extrahepatic disease.

This workflow is distinct from other related clinical situations. It does not apply to:

  • Screening: This article is not for asymptomatic, high-risk patients undergoing routine surveillance for liver cancer. That falls under the Screening scenario, which typically involves ultrasound.
  • Active Surveillance of Known Lesions: This guidance is not for monitoring a previously identified liver observation that did not meet criteria for definitive cancer diagnosis. That is a separate scenario focused on tracking lesion stability or growth.
  • Post-Treatment Evaluation: This workflow is not for assessing treatment response after locoregional therapy (like ablation or chemoembolization) or systemic therapy. That requires specific post-treatment imaging protocols to differentiate viable tumor from treatment-related changes.

Applying this staging pathway is appropriate only after a primary liver cancer diagnosis has been made and before initial treatment has been administered.

What Anatomic and Pathologic Questions Are You Answering with Staging Imaging?

Staging primary liver cancer is not about making the initial diagnosis but about precisely defining its extent to guide management. The imaging study must answer several critical questions that determine the patient’s eligibility for curative-intent therapies versus palliative approaches. The “differential” in this context is less about different diseases and more about different stages of the same disease.

Intrahepatic Tumor Burden: The most fundamental question is the number and size of tumors within the liver. Is there a single, resectable lesion? Are there multiple tumors confined to one lobe? Or is the disease multifocal and bilobar? High-quality imaging must detect not only the primary mass but also small, clinically significant satellite nodules that would preclude surgical resection.

Vascular Invasion: A key determinant of prognosis and treatment is the presence of tumor invasion into the portal or hepatic venous systems. Macroscopic vascular invasion is a contraindication for liver transplantation and often directs patients toward non-curative therapies. The imaging study must have high sensitivity for detecting tumor thrombus, which can be subtle.

Extrahepatic Spread: The workup must assess for metastatic disease outside the liver. The most common sites include regional lymph nodes (porta hepatis, celiac axis), the lungs, adrenal glands, and bones. Identifying extrahepatic disease immediately upstages the patient and typically makes them a candidate for systemic therapy rather than liver-directed treatments.

Biliary Duct Involvement: While more characteristic of cholangiocarcinoma, assessing for biliary obstruction or invasion is also relevant for staging, as it can affect liver function and surgical planning. This is particularly important for tumors located near the hepatic hilum.

Why Is Multiphasic MRI of the Abdomen the Recommended Staging Study?

The ACR designates `MRI abdomen without and with IV contrast` as Usually Appropriate for the initial staging of primary liver cancer because of its superior soft-tissue contrast and high diagnostic accuracy for the key staging questions without using ionizing radiation.

A dedicated multiphasic liver MRI protocol provides detailed anatomical and functional information. The dynamic contrast-enhanced sequences—typically including late arterial, portal venous, and delayed phases—are essential for characterizing the enhancement patterns of HCC and other liver tumors. This allows for confident identification of key features like arterial phase hyperenhancement and portal venous phase “washout,” which are hallmarks of HCC. MRI is particularly sensitive for detecting small satellite lesions and differentiating tumor thrombus from bland (non-cancerous) thrombus in the portal vein.

While MRI is the top-rated modality, it’s important to understand how it compares to other options:

  • CT abdomen with IV contrast multiphase: This study is also rated Usually Appropriate. It is an excellent alternative, especially when MRI is contraindicated (e.g., incompatible medical devices, severe claustrophobia) or less available. Modern multiphase CT provides superb evaluation of vascular invasion and extrahepatic spread. However, it involves a significant radiation dose (☢☢☢☢ 10-30 mSv) and has slightly lower sensitivity for small intrahepatic lesions compared to MRI with a hepatobiliary-specific contrast agent.
  • US abdomen transabdominal: This is rated Usually not appropriate for staging. While ultrasound is the primary tool for screening, it is not sufficient for staging. It has limited sensitivity for multifocal disease, cannot reliably assess for extrahepatic spread, and its ability to detect vascular invasion is operator-dependent and less definitive than MRI or CT.
  • MRI abdomen without IV contrast: This is also rated Usually not appropriate. Without intravenous contrast, the dynamic vascular information crucial for characterizing liver lesions and assessing vascularity is lost, rendering the study inadequate for staging purposes.

When ordering, it is critical to specify “multiphasic liver protocol” to ensure the radiology department performs the correct dynamic sequences. If available, using a hepatobiliary contrast agent (like gadoxetate disodium) can further increase sensitivity for small lesions on delayed imaging.

What’s Next After MRI? A Guide to the Downstream Workflow

The results of the staging MRI will directly guide the multidisciplinary tumor board discussion and subsequent management plan. The workflow branches based on the key findings related to tumor extent.

If the MRI shows localized, resectable disease: For a patient with a single tumor, no evidence of vascular invasion, and preserved liver function, the next step is typically surgical consultation for potential resection or transplant evaluation. The MRI provides the roadmap for the surgeon, detailing the tumor’s relationship to major vessels and biliary ducts.

If the MRI shows intermediate-stage disease: This often includes patients with multifocal tumors confined to the liver or a tumor with segmental vascular invasion, but no extrahepatic spread. These patients are generally not candidates for surgery. The downstream workflow involves consultation with interventional radiology for liver-directed locoregional therapies, such as transarterial chemoembolization (TACE) or radioembolization (Y-90).

If the MRI shows advanced-stage disease: If the scan reveals macroscopic vascular invasion (e.g., in the main portal vein) or extrahepatic metastatic disease (e.g., in lymph nodes, lungs, or adrenal glands), the patient is considered to have advanced disease. The next step is a consultation with medical oncology to initiate systemic therapy, typically with tyrosine kinase inhibitors and/or immunotherapy.

If the MRI is indeterminate: In rare cases, a finding may be equivocal (e.g., an atypical lesion or uncertainty about subtle vascular invasion). The next step may involve a targeted biopsy of the indeterminate finding or a different imaging modality, such as a contrast-enhanced CT if not already performed, to provide complementary information before a final treatment decision is made.

Pitfalls to Avoid When Ordering and Interpreting Staging Imaging

Navigating the staging process for primary liver cancer requires attention to detail to avoid common errors that can lead to incorrect staging and suboptimal treatment.

  • Ordering the Wrong Protocol: Requesting a “routine” MRI of the abdomen without specifying a multiphasic liver protocol is a frequent pitfall. This may result in a study lacking the essential arterial, portal venous, and delayed phases needed for accurate characterization and staging.
  • Overlooking Contraindications: Failing to screen for contraindications to MRI (e.g., certain pacemakers, cochlear implants) or gadolinium-based contrast agents (e.g., acute kidney injury, severe chronic kidney disease) can cause delays and patient safety issues. Always have a plan to pivot to multiphasic CT if MRI is not feasible.
  • Incomplete Evaluation for Extrahepatic Disease: While abdominal MRI/CT is the core study, remember to review the lung bases and visible bones for metastases. Depending on the findings and local guidelines, a dedicated chest CT (rated May be appropriate (Disagreement) by the ACR) may be necessary to fully exclude pulmonary metastases.
  • Ignoring Clinical Context: The imaging findings should always be integrated with clinical data, including the patient’s liver function (Child-Pugh score), performance status, and serum tumor markers like AFP. Staging systems like the Barcelona Clinic Liver Cancer (BCLC) system rely on both imaging and clinical factors.

If there is any ambiguity in the imaging report or discrepancy with the clinical picture, direct communication with the reporting radiologist is the most effective next step to clarify findings and ensure accurate staging.

Related ACR Topics and Tools

This article focuses on a single, specific clinical scenario. For a comprehensive overview of imaging for all related presentations, from screening to post-treatment surveillance, please consult the parent topic guide. Additional tools are available to help select appropriate studies and understand imaging parameters.

Frequently Asked Questions

Why is MRI preferred over CT for staging liver cancer if both are rated ‘Usually Appropriate’?

MRI is often preferred due to its superior soft-tissue contrast, which provides higher sensitivity for detecting small satellite tumors and characterizing subtle vascular invasion. It also avoids the use of ionizing radiation, which is a consideration in patients who may require multiple future scans. However, multiphasic CT is an excellent and widely used alternative, especially if MRI is contraindicated or unavailable.

What should I order if my patient has a contraindication to MRI or gadolinium contrast?

If a patient cannot undergo an MRI or receive gadolinium-based contrast agents (e.g., due to an incompatible implanted device or severe renal impairment), the ACR-recommended alternative is a `CT abdomen with IV contrast multiphase`. This study provides the necessary dynamic vascular information for staging, though it involves ionizing radiation.

Is a PET/CT scan necessary for the initial staging of primary liver cancer?

According to the ACR, FDG-PET/MRI or PET/CT is `Usually not appropriate` for the initial routine staging of hepatocellular carcinoma (HCC). While it can detect extrahepatic metastases, its sensitivity for well-differentiated HCC is variable. Its role is typically reserved for select cases, such as in transplant evaluation or when other imaging is equivocal for metastatic disease.

Do I need to order a separate CT of the chest to look for lung metastases?

The ACR panel notes disagreement on this, rating both `CT chest with IV contrast` and `CT chest without IV contrast` as `May be appropriate (Disagreement)`. The lung bases are visualized on the abdominal MRI or CT, which can serve as a screen. A dedicated chest CT is often performed if there is high suspicion for metastases, if the patient is a candidate for curative therapy like resection or transplant, or based on institutional protocol.

What is the role of contrast-enhanced ultrasound (CEUS) in this scenario?

For staging, the ACR rates `US abdomen with IV contrast` as `Usually not appropriate`. While CEUS is a valuable tool for the characterization of a focal liver lesion (differentiating benign from malignant), it is not suited for comprehensive staging as it cannot evaluate the entire liver for multifocal disease or assess for extrahepatic spread in the abdomen and chest.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026